Leading scientists from the UPcare Group met with the White House Covid Task Force recently to discuss the positive results in an Anti SARS-CoV-2 screening program conducted under contract by the Doherty Institute and other supporting data for three of UPcare’s compounds, with a view to UPcare’s products being used in hospitals and medical centres across the US.
The UPcare Group have successfully identified that one of their natural compounds, UP-A, can successfully inhibit SARS-CoV-2 infection in Vero cells. A preliminary screen conducted under contract by the Doherty Institute, showed low micromolar inhibition of SARS-CoV-2 by UP-A and similar levels of inhibition when combined with UPcare’s other compounds UP-U and UP-P. These results and potential synergistic effects are to be confirmed and explored further.
The 3 natural compounds, namely UP-A, UP-U, and UP-P, are botanical extracts that have been used in medicinal formulations for centuries. They are derived from loquat, knotweed and chiretta.
The extracts used in each compound contain no hormones or residues. All of the critical ingredients have undergone long term studies and have passed assessments for subchronic and developmental toxicity, with no adverse reaction or side effects reported in humans.
Two of the natural compounds UP-U and UP-P are present in UPcare Groups product UPplus KBD Spray which is currently being sold over the counter and online as a TGA and FDA approved respiratory health and immune boosting product. The UPcare Group which is currently privately funded are now in the process of raising a further 50 million AUD to carry out the human trials required to prove their TGA approved products UPplus A Spray and UPplus A Capsules containing all 3 compounds can also eliminate SARS-CoV-2 in infected individuals. Manufacturing for the UPplus A Spray and UPplus A Capsules will begin early 2021.
If the UPcare Group’s human trials are successful, it will be approved as a natural formulation available on the global market in the fight against SARS-CoV-2.
